Product Description
Multispecific antibody encoded by NTX-472 preferentially engaged CD47 in presence of co-engagement of CD20 and CD19.One dose of NTX-472 in vivo rapidly depleted B cells with no detectable binding to red blood cells. Systemically delivered, mRNA encoded multi-specific protein. (Sourced from: https://www.nutcrackerx.com/pipeline/)
Mechanisms of Action: CD19 Inhibitor,CD20 Inhibitor,SIRPa Inhibitor
Novel Mechanism: Yes
Modality: Trispecific Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nutcracker Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Autoimmune Disease Unspecified|Lymphoma, B-Cell
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|